NeoGenomics Inc. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
2,033.00
1,132.00
2,535.00
5,723.00
846.00
2,640
Depreciation, Depletion & Amortization
4,412.00
5,640.00
7,142.00
23,209.00
22,591.00
21,732
Other Funds
3,704.00
3,195.00
3,731.00
25,354.00
26,841.00
7,901
Funds from Operations
10,149.00
9,967.00
8,338.00
42,840.00
48,586.00
32,273
Changes in Working Capital
7,922.00
517.00
1,945.00
21,363.00
30,549.00
12,513
Net Operating Cash Flow
2,227.00
9,450.00
6,393.00
21,477.00
18,037.00
44,786
Capital Expenditures
2,011.00
3,772.00
2,215.00
7,536.00
13,690.00
Sale of Fixed Assets & Businesses
-
-
-
1,035.00
-
Net Investing Cash Flow
2,011.00
9,602.00
75,155.00
6,501.00
13,690.00
Issuance/Reduction of Debt, Net
6,783.00
7,863.00
57,558.00
25,361.00
6,681.00
Net Financing Cash Flow
2,750.00
29,007.00
58,493.00
25,871.00
4,095.00
Net Change in Cash
2,966.00
28,855.00
10,269.00
10,895.00
296.00
Free Cash Flow
216.00
5,678.00
4,178.00
13,941.00
4,347.00
Net Assets from Acquisitions
-
5,830.00
72,940.00
-
-
Change in Capital Stock
9,533.00
36,870.00
935.00
51,232.00
2,586.00
Exchange Rate Effect
-
-
-
-
44.00

About NeoGenomics

View Profile
Address
12701 Commonwealth Drive
Fort Myers Florida 33913
United States
Employees -
Website http://www.neogenomics.com
Updated 07/08/2019
NeoGenomics, Inc. provides cancer diagnostics and pharma services. It operates through a network of cancer focused testing laboratories to provide genetic and molecular testing services. It offers various testing services, including Cytogenetics, Fluorescence In-Situ Hybridization, Flow Cytometry, Immunohistochemistry, Molecular testing and Pathology consultation.